IMMEDIATE IMMUNITY
DEAD

Serial Number

78223167

Owner

Xenerex Biosciences

Attorney

Salima A. Merani, Esq.

Filing Date

Mar 7, 2003

Add to watchlist:

No watchlists yet
View on USPTO

IMMEDIATE IMMUNITY Trademark

Serial Number: 78223167

IMMEDIATE IMMUNITY is a trademark filed by Xenerex Biosciences on March 7, 2003. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Xenerex Biosciences (6 trademarks)

9393 Towne Centre Drive, Suite 200
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

March 7, 2003

Registration Date

Not Registered

Goods & Services

Biochemicals, namely, monoclonal antibodies and fragments thereof, for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; cell lines for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; vaccines, namely, therapeutic vaccines, polypeptide vaccines, live vaccines, viral vaccines, nucleic acid vaccines, vaccines containing antibodies, polypeptides, protein and nucleic acids, vaccine recipients, vaccine carriers, and vaccines adjuvants

Biochemicals, namely, monoclonal antibodies and fragments thereof, for research, development and manufacturing of pharmaceuticals; cell lines for use in the manufacture of pharmaceuticals; biochemical products for use in the development of vaccines, namely therapeutic vaccines, polypeptide, viral and nucleic acids vaccines, antibodies, polypeptides, protein and nucleic acids for vaccine use; and vaccine excipients, vaccine carriers, and vaccine adjuvants for medical science

Scientific, pharmaceutical and biological product development consultation, namely development consultation for vaccines and vaccine-related products; pharmaceutical and biological product development for others; vaccine and immunotherapy research and development; pharmaceutical, biomedical and biotechnological development of therapeutic vaccines and antibody-based products

Filing History

ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 18, 2004 ABN2
NON-FINAL ACTION E-MAILED
Sep 4, 2003 GNRT
ASSIGNED TO EXAMINER
Aug 27, 2003 DOCK